PAD Formulary : Surrey Heartlands
PAD - Prescribing Advisory Database
PLEASE NOTE : This is a development system.

For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.

You are here : Home > PAD Profile : Adalimumab - Psoriasis (Hand and foot)

PAD Profile : Adalimumab - Psoriasis (Hand and foot)

Keywords :
biologic
Brand Names Include :
Humira, Hyrimoz, Imraldi, Amgevita, Hulio, Yuflyma

Traffic Light Status

Status 1 of 2.

Status :
Red
Formulations :
  • Not Specified
Trust Alignment :
Primary Care
ASPH
RSFT
SASH
SABP
Links :
BNF NICE SPC
Comments :
No comments returned.
Documents :

Status 2 of 2.

Status :
See Below
Formulations :
  • Not Specified
Trust Alignment :
Primary Care
ASPH
RSFT
SASH
SABP
Links :
BNF NICE SPC
Comments :
No comments returned.
Documents :

Guidelines

No guidelines returned.

Other Drugs

No drugs returned.

Other Indications

Additional Documents

Type
Document
Review Date
Evidence Review
Psoriasis (hand and foot) biologic drugs - PCN evidence review - April 2011

Committee Recommendations

Date
Committee Name
Narrative
08 July 2019
Surrey & North West Sussex Area Prescribing Committee (formerly Prescribing Clinical Network)

The Medicines and Healthcare Products Regulatory Agency (MHRA) recommends to prescribe biological products by brand name to ensure that substitution of a biosimilar product does not occur when the medicine is dispensed by the pharmacist. Https://www/gov/uk/drug-safety-update/biosimilar-products

Primary care prescriber should ensure that patient medication records include any medicine for which prescribing remains the responsibility of secondary or tertiary care. This will ensure that GP records, which are accessed by other healthcare providers, are a true and accurate reflection of the patient's medication.

01 April 2011
Surrey & North West Sussex Area Prescribing Committee (formerly Prescribing Clinical Network)
The committee members noted that the evidence to support the use of biologics in this cohort of patients was limited but positive. They noted that patients with hand and foot psoriasis are treated initially like patients with plaque psoriasis but are unable to progress to biologic treatments because NICE have only considered the licensed indication chronic plaque psoriasis and that the measurement tools for determining disease severity are not applicable in this patient cohort. A tick box proforma is to be completed by the clinician to inform the PCT and secure funding

Associated BNF Codes

13. Skin
13.05.03. Drugs affecting the immune response
This site uses its own and third party cookies to function properly and to improve performance, to maintain the session and to personalise user experience, as well as to obtain anonymous statistics about the use of the website. Visit our Privacy and Cookie Policy for more information on our data collection practices. By clicking 'Accept' you agree to our use of cookies for the purposes listed.
 Learn More